OA
TRDA icon

Oracle Alpha’s Entrada Therapeutics TRDA Stock Holding History

Oracle Alpha’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$246K Buy
17,341
+4,841
+39% +$68.5K 0.44% 114
2023
Q4 		$189K Buy
+12,500
New +$185K 0.24% 196

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Oracle Alpha's TRDA Position: Q1 2024 in Review

Oracle Alpha increased its Entrada Therapeutics (TRDA) stake by 39% in Q1 2024, buying an estimated $68.5K and bringing the position to 17,341 shares worth $246K. The position accounts for 0.44% of the portfolio, ranked #114.

Oracle Alpha first reported a position in TRDA in Q4 2023 and has held it in 2 quarters since. 77 funds tracked by Wall St. Rank hold TRDA as of Q1 2024.

  • Oracle Alpha held 17,341 shares of Entrada Therapeutics worth $246K as of Q1 2024.
  • Oracle Alpha bought 4,841 Entrada Therapeutics shares in Q1 2024, an estimated $68.5K.
  • Entrada Therapeutics made up 0.44% of Oracle Alpha's portfolio in Q1 2024, its #114 holding.
  • Oracle Alpha first reported a position in Entrada Therapeutics in Q4 2023 and has held it in 2 quarters since.
  • 77 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2024.

Based on Oracle Alpha's 13F filing for Q1 2024, filed 15 May 2024.